6:28 AM ET
8-K
Regulatory Approval
Perspective Therapeutics Regulatory Approval
Perspective Therapeutics announced that the FDA has granted Fast Track Designation for PSV359, an investigational FAP-targeted alpha-particle therapy. The designation is for the treatment of adult patients with locally advanced unresectable and/or metastatic fibroblast activation protein-positive solitary fibrous tumors (SFTs).